Arch Therapeutics to Present Status Update and Milestone Overview at Noble Financial Capital Markets' Tenth Annual Equity

Arch Therapeutics to Present Status Update and Milestone Overview at Noble 
Financial Capital Markets' Tenth Annual Equity Conference 
Company Presentation Will Be Webcast Live on Wednesday, January 22 at
10:30AM EST 
WELLESLEY, MA -- (Marketwired) -- 01/14/14 --   Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company
and developer of the AC5 Surgical Hemostatic Device(TM), a novel
product aimed at controlling bleeding and fluid loss in order to
provide faster and safer surgical and interventional care, is pleased
to announce that Company CEO, Terrence W. Norchi, M.D., is scheduled
to present at "TEN"; Noble Financial Capital Markets' Tenth Annual
Equity Conference in Sandpiper Bay, Florida, on Wednesday, January 22
at 10:30AM Eastern Time. 
Dr. Norchi will be providing a summary of events to-date and a
strategic overview including milestones planned for 2014. The
presentation will be provided via a live audio and high-definition
video webcast and a copy of the Arch Therapeutics presentation
materials can be accessed at the following URL:
or through the Noble Financial websites at:, or 
Arch Therapeutics recommends registering at least 10 minutes prior to
the start of the presentation to ensure timely access. You will
require a Microsoft Silverlight viewer (a free download from the
presentation link) to participate. 
The webcast and presentation will also be archived on the Arch
website for 90 days following the event at 
Dr. Norchi advises, "We have had an excellent first quarter and
remain enthusiastic about our development pace and the receptivity of
the commercial markets to the benefits and features of our AC5
Surgical Hemostatic Device(TM). Over the coming weeks, we will
further discuss our upcoming milestones, which we plan to deliver in
About Noble Financial
 Noble Financial Capital Markets was
established in 1984; 2014 marks its 30th Anniversary. Noble Financial
is an equity research driven, full-service, investment banking
boutique focused on life sciences, technology and media, emerging
growth, companies. The company has offices in Boston, Los Angeles,
and Boca Raton, FL. In addition to non-deal road shows and
sector-specific conferences throughout the year, Noble Financial
hosts its large format annual equity conference in January in South
Florida featuring 120 - 150 presenting companies from across North
America and total attendance of close to 600. For more information: 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
is a medical device company developing a novel approach to stop
bleeding (hemostasis) and control leaking (sealant) during surgery
and trauma care. Arch is developing products based on an innovative
self-assembling peptide technology platform to make surgery and
interventional care faster and safer for patients. Arch's flagship
development stage product candidate, known as AC5(TM), is being
designed to achieve hemostasis in minimally invasive and open
surgical procedures. Find out more at  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at 
On Behalf of the Board,
 Terrence W. Norchi, MD.
 Arch Therapeutics,
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Press spacebar to pause and continue. Press esc to stop.